Preparation and identification of transfer factor specific to Staphylococcus aureus in vitro

Abstract

The objective of the study was to explore the methods for preparing transfer factor specific to Staphylococcus aureus (SA-STF) in vitro. Under the optimum conditions, the spleen cells of rabbits were immunized with SA in vitro to prepare SA-STF, and the immune activities were identified with the phagocytosis and sterilization, skin delayed-type hypersensitivity, and immune protection tests. The concentration of polypeptide was 2.26 ± 0.27 mg/mL, and ribose was 0.684 ± 0.094 mg/mL. The phagocytosis and sterilization rates of the STF group were 70.9 ± 12.4% and 62.1 ± 12.2%, respectively, and compared with the non-specific transfer factor (NTF) group, there were no significant differences (P = 0.074 and 0.069, respectively). The skin was inflamed and marked nodules formed at the injection site in the mice of the STF group rather than the NTF and control groups. The survival rate of the STF-1 group was significantly higher than the survival rates of the STF-2 (P = 0.024) and NTF groups (P = 0.016). SA-STF was prepared and characterized successfully in vitro, and it probably is a biological candidate for therapy or adjuvant therapy for diseases caused by Staphylococcus aureus.

CD8+ T cells produce a dialyzable antigen-specific activator of dendritic cells

“…6C) after challenge. Consistent with this induction of responses relevant for the control of S. aureus [31], MRSA:DLE-treated mice had smaller lesion sizes (Fig. 6D) and a nonsignificant trend toward reduction of CFUs ( Supplemental Fig.…”

The Efficacy of Prepared Specific Pseudomonas aeruginosa Transfer Factor to Protect Mice against Experimental Challenge

“…These results demonstrated the efficacy of the prepared TFt in the passive transport of the DTH-skin reaction to non-sensitized recipient individuals. The classical response to TF treatment is the transmission of DTH-skin reactivity to previously non sensitized individuals (Lawrence, 1949;Zhou et al, 2015).…”

“…While, higher survival rate in the TFt recipient mice confirmed the ability of the prepared TFt to protect the mice against challenge with this pathogen. Transfer factor is an immunoregulatory agent has been successfully used in the human and veterinary medicine as immunotherapy against the infections caused by various types of bacterial, viral, parasitic and fungal pathogens, as well as the diseases associated with defects in the cellular immune responses (Al-Graibawi et al, 2002;Levine et al, 2011;Viza et al, 2013 andZhou et al, 2015). The cellular immune responses play vital role in the host defences against pulmonary infection with P. aeruginosa (Pier and Markham, 1982;Buret et al, 1993).…”